Effect of citalopram versus escitalopram on quality of life in the treatment of the acute phase of major depressive disorder: A comparative, open-label study;Majör depresif bozukluǧun akut dönem tedavisinde sitalopram ve essitalopram'in yaşam kalitesi üzerine etkisi: Karşilaştirmaliaçik bir çalişma

Klinik Psikofarmakoloji Bulteni

Volumn 21, Issue 3, 2011, Pages 210-218

  Aydemir, Ömer ^a   Ergün, Hakan ^b   Kesebir, Sermin ^c   Soygür, Haldun ^d   Tulunay, Cankat ^b  

^a Bayar Üniversitesi Tip Fakültesi Psikiyatri AD ö retim üyesi   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c Erenköy Ruh Sa li i ve Hastaliklari Hastanesi   (Turkey)

^d Ankara Asker Hastanesi Psikiyatri Klini i   (Turkey)

Author keywords

Citalopram; Escitalopram; Major depressive disorder; Quality of life; Remission

Indexed keywords

CITALOPRAM; ESCITALOPRAM;

ACUTE DISEASE; ADULT; ARTICLE; DISEASE DURATION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OPEN STUDY; OUTPATIENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SHORT FORM 36; SOCIAL INTERACTION; TREATMENT RESPONSE;

EID: 80052990380     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20110627111533     Document Type: Article

References (19)

1. Fava GA, Ruini C, Belaise C. The concept of recovery in major depression. Psychol Med 2007; 37(3): 307-17.
2. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW. et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48(9):851-5.
3. Aydemir Ö, Ergün H, Soygür H, Kesebir S, Tulunay C. Major depresif bozuklukta yaşam kalitesi: kesitsel bir çali{dotless}şma. Turk Psikiyatri Derg 2009; 20(3): 205- 12.
4. da Rocha NS, Power MJ, Bushnell DM, Fleck MP. Is there a measurement overlap between depressive symptoms and quality of life? Compr Psychiatry 2009; 50(6):549-55.
5. Moses T, Leuchter AF, Cook I, Abrams M. Does the clinical course of depression determine improvement in symptoms and quality of life? J Nerv Ment Dis 2006; 194(4): 241-8.
6. Berlim MT, Pargendler J, Brenner J, Fleck MP. Significant improvement in the quality of life of Brazilian depressed outpatients 12 weeks following the start of antidepressants. Psychiatry Res 2007; 153(3): 253-9.
7. Sobocki P, Ekman M, Agren H, Krakau I, Runeson B, Mårtensson B. et al. Health related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health 2007; 10(2):153-60.
8. Reed C, Monz BU, Perahia DG, Gandhi P, Bauer M, Dantchev N. et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord 2009; 113(3): 296-302.
9. Trkulja V. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-tohead randomized trials. Croat Med J 2010; 51(1): 61-73.
10. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; 15;(2):CD006532.
11. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20(3): 131-7.
12. Yevtushenko VY, Belous AI, Yevtushenko YG. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, doubleblind, active-controlled study in adult outpatients. Clin Ther 2007; 29(11): 2319-32.
13. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473-83.
14. Koçyiǧit H, Aydemir Ö, Ölmez N, Memiş A. Ki{dotless}sa Form-36 (KF-36)'ni{dotless}n Türkçe Versiyonunun Güvenilirliǧi ve Geçerliliǧi. Ilaç ve Tedavi Dergisi 1999; 12(1): 102-6.
15. Demiral Y, Ergör G, Ünal B, Semin S, Akvardar Y, Kivircik B. et al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health 2006; 9:247.
16. EuroQoL Group. EuroQoL-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3):199-208.
17. Eser E, Dinç G, Cambaz S, Özyurt B, Nesanir N, Şerifhan M, et al. EURO-QoL (EQ-5D) indeksinin toplum standartlari{dotless} ve psikometrik özellikleri: Manisa kent toplumu örneklemi. 2. Saǧli{dotless}kta Yaşam Kalitesi Kongresi Bildiri Özetleri Kitabi{dotless} Meta Basi{dotless}mevi, İzmir, 2007; p.78.
18. Akdemir A, Örsel S, Daǧ İ, Türkçapar H, Işcan N, Özbay H. Hamilton Depresyon Derecelendirme Ölçeǧi (HDDÖ)'nin geçerliǧi, güvenirliǧi ve klinikte kullani{dotless}mi{dotless}. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996; 4(4): 251-9.
19. Skevington SM, Wright A. Changes in the quality of life of patients receiving antidepressant medication in primary care: validation of the WHOQOL-100. Br J Psychiatry 2001; 178:261- 7.